{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-012303","form_type":"8-K","ticker":"RVPH","cik":"0001742927","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2026-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.838043+00:00","generated_at":"2026-05-15T06:08:23.904735+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Reviva targets brilaroxazine patent extension to 2046, plans API switch in RECOVER-2 trial","bullets":["Filed composition of matter patent on new brilaroxazine form; pursuing accelerated review to extend exclusivity potentially through 2046.","Preparing to seek FDA alignment to switch API and formulation in RECOVER-2; feedback expected mid-2026.","RECOVER-2 trial activities start Q2 2026, patient enrollment Q3 2026, completion expected Q4 2027.","Closed $10M financing on March 20, 2026; pro forma cash ~$23M, expected to fund operations into Q1 2027.","Evaluating strategic alternatives to maximize brilaroxazine value; recent reverse stock split and financing were difficult but necessary."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-012303","json":"https://secwatch.observer/filing/0001437749-26-012303.json","markdown":"https://secwatch.observer/filing/0001437749-26-012303.md","text":"https://secwatch.observer/filing/0001437749-26-012303.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926012303/0001437749-26-012303-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926012303/rvph20260414_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:08:23.904735+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}